208 related articles for article (PubMed ID: 27923207)
1. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
Lee YC; Chang CH; Dong YH; Lin JW; Wu LC; Hwang JS; Chuang LM
Int J Cardiol; 2017 Feb; 228():1007-1014. PubMed ID: 27923207
[TBL] [Abstract][Full Text] [Related]
2. Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population-based cohort study in China.
Xu Y; Wang T; Yang Z; Lin H; Shen P; Zhan S
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):635-643. PubMed ID: 32383226
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
Hsu PF; Sung SH; Cheng HM; Shin SJ; Lin KD; Chong K; Yen FS; Yu BH; Huang CT; Hsu CC
J Clin Endocrinol Metab; 2018 Oct; 103(10):3611-3619. PubMed ID: 30113697
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.
Chang CH; Chang YC; Lin JW; Chen ST; Chuang LM; Lai MS
J Clin Endocrinol Metab; 2015 Mar; 100(3):1121-9. PubMed ID: 25555040
[TBL] [Abstract][Full Text] [Related]
7. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
[TBL] [Abstract][Full Text] [Related]
8. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
9. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
Ou HT; Chang KC; Li CY; Wu JS
Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
[TBL] [Abstract][Full Text] [Related]
10. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
Fadini GP; Avogaro A; Degli Esposti L; Russo P; Saragoni S; Buda S; Rosano G; Pecorelli S; Pani L;
Eur Heart J; 2015 Sep; 36(36):2454-62. PubMed ID: 26112890
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
[TBL] [Abstract][Full Text] [Related]
13. Association of Renal and Cardiovascular Safety With DPP-4 Inhibitors vs. Sulfonylureas in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Yang CT; Lin WH; Li LJ; Ou HT; Kuo S
Clin Pharmacol Ther; 2021 Aug; 110(2):464-472. PubMed ID: 33866549
[TBL] [Abstract][Full Text] [Related]
14. Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan.
Hsiao PJ; Wu KL; Chiu SH; Chan JS; Lin YF; Wu CZ; Wu CC; Kao S; Fang TC; Lin SH; Chen JS
Clin Exp Nephrol; 2017 Aug; 21(4):694-704. PubMed ID: 27599981
[TBL] [Abstract][Full Text] [Related]
15. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
[TBL] [Abstract][Full Text] [Related]
16. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403
[TBL] [Abstract][Full Text] [Related]
17. Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study.
Tseng YH; Tsan YT; Chan WC; Sheu WH; Chen PC
Diabetes Care; 2015 Nov; 38(11):2068-74. PubMed ID: 26307605
[TBL] [Abstract][Full Text] [Related]
18. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan.
Chiu CC; Huang CC; Chen YC; Chen TJ; Liang Y; Lin SJ; Chen JW; Leu HB; Chan WL
Intern Med; 2013; 52(9):939-46. PubMed ID: 23648711
[TBL] [Abstract][Full Text] [Related]
20. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
Wamil M; McMurray JJV; Scott CAB; Coleman RL; Sun Y; Standl E; Rydén L; Holman RR
Diabetes Res Clin Pract; 2020 Dec; 170():108488. PubMed ID: 33035598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
